Neutralizing antibodies are known to have a crucial role in protecting against SARS-CoV-2
infection and have been suggested to be a useful correlate of protection for vaccine clinical …

Adaptive immunity provides protection against infectious and malignant diseases. These
effects are mediated by lymphocytes that sense and respond with targeted precision to …

Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …

Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron
variant, designated as a variant of concern by the World Health Organization, carries …

Abstract SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-
19 1, 2, 3, 4, 5. The dynamics of antibody-secreting plasmablasts and germinal centre B …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies …

The potential for future coronavirus outbreaks highlights the need to broadly target this
group of pathogens. We used an epitope-agnostic approach to identify six monoclonal …